عرض بسيط للتسجيلة

المؤلفDanjuma, Mohammed I.
المؤلفKaul, Ridhima
المؤلفAlyaarabi, Tamader
المؤلفElsayed, Basant
المؤلفElshafei, Mohamed
تاريخ الإتاحة2024-02-14T06:09:35Z
تاريخ النشر2023-02-16
اسم المنشورEuropean Journal of Internal Medicine
المعرّفhttp://dx.doi.org/10.1016/j.ejim.2023.02.009
الاقتباسDanjuma, M. I., Kaul, R., Alyaarabi, T., Elsayed, B., & Elshafei, M. (2023). Colchicine and mortality outcomes in patients with coronavirus disease (COVID-19). European Journal of Internal Medicine, 112, 126-127.
الرقم المعياري الدولي للكتاب0953-6205
معرّف المصادر الموحدhttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85159791904&origin=inward
معرّف المصادر الموحدhttp://hdl.handle.net/10576/51789
الملخصOne of the therapeutic hallmarks of the ongoing (COVID-19) pandemic has been the different iterations of successful and sometimes unsuccessful attempts at re-purposing of drugs with pre-existing market authorization for use in COVID-19 patients. We therefore read with interest Perricone et al’s., recent report on the clinical outcomes of hospitalized COVID-19 patients exposed to colchicine [1]. This randomized controlled clinical trial (RCT) evaluating efficacy and safety of generic colchicine found no significant difference in the primary composite endpoints of intensive care admissions (ICU) and the need for mechanical ventilation between patients exposed to colchicine added to standard of care (N = 77) vs. controls (N = 75) stabilized on usual standard of care (mechanical ventilation 5.2% vs 4%, ICU 1.3% vs 5.3%, death 9.1% vs. 6.7%, overall 11 (14.3%) vs. 10 (13.3%) patients, P=not significant). Perricone et al’s., report has “arrived” at critical time against a backdrop of ongoing uncertainty regarding the exact relationship between colchicine exposure and hard clinical endpoints in COVID-19 patients. Discordant studies from both observational as well as clinical trials have reported both mortality-reducing propensity of colchicine in these cohorts of patients, as well null effect by others [2].
اللغةen
الناشرElsevier
الموضوعCOVID-19
randomized controlled clinical trial
العنوانColchicine and mortality outcomes in patients with coronavirus disease (COVID-19)
النوعArticle
الصفحات126-127
رقم المجلد112
ESSN1879-0828
dc.accessType Open Access


الملفات في هذه التسجيلة

Thumbnail

هذه التسجيلة تظهر في المجموعات التالية

عرض بسيط للتسجيلة